SCHEMBL30201702

SCHEMBL30201702

NC(=O)c1ccc2cc[nH]c2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.70
HSD17B10 Q99714 2/20 0.70
ENPP2 Q13822 2/20 0.70
KDM4E B2RXH2 1/20 0.70
HPGD P15428 1/20 0.70
TYR P14679 1/20 0.52
GHSR Q92847 2/20 0.50
AR P10275 1/20 0.50
MAPT P10636 1/20 0.50
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
ESR1 P03372 2/20 0.49
F2 P00734 1/20 0.49
LCK P06239 1/20 0.48
SMYD3 Q9H7B4 1/20 0.48
CYP2A6 P11509 1/20 0.47
AHR P35869 3/20 0.47
CMA1 P23946 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL50552 1.00 ALDH1A1 (0.70) ALDH1A1HSD17B10ENPP2KDM4EHPGD
Hydrochloric Acid SCHEMBL8915608 0.98 ALDH1A1 (0.68) ALDH1A1HSD17B10ENPP2KDM4EHPGD
Bromide SCHEMBL8916350 0.98 ALDH1A1 (0.68) ALDH1A1HSD17B10ENPP2KDM4EHPGD
Iodide SCHEMBL8916427 0.98 ALDH1A1 (0.68) ALDH1A1HSD17B10ENPP2KDM4EHPGD
SCHEMBL29566955 0.98 ALDH1A1 (0.68) ALDH1A1HSD17B10ENPP2KDM4EHPGD
Benzene SCHEMBL27399226 0.96 ALDH1A1 (0.71) ALDH1A1HSD17B10ENPP2KDM4EHPGD
Oxalic Acid SCHEMBL8915851 0.95 ALDH1A1 (0.69) ALDH1A1HSD17B10ENPP2KDM4EHPGD
Phosphoric Acid SCHEMBL8915701 0.93 ALDH1A1 (0.62) ALDH1A1HSD17B10ENPP2KDM4EHPGD
Sulfuric Acid SCHEMBL7456727 0.93 ALDH1A1 (0.62) ALDH1A1HSD17B10ENPP2KDM4EHPGD
Acetic Acid SCHEMBL8914629 0.93 ALDH1A1 (0.67) ALDH1A1HSD17B10ENPP2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2024-01-18 US claimed
EP-4159725-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2023-04-05 EP claimed
WO-2023009330-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC (US) 2023-02-02 WO claimed
US-20250236624-A1 Heterocyclic Compounds as RET Kinase Inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-24 US disclosed
WO-2024158872-A1 1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF THE ROCKEFELLER UNIVERSITY (US) 2024-08-02 WO disclosed
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2024-01-18 US disclosed
US-20230339954-A1 Heterocyclic Compounds as RET Kinase Inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-10-26 US disclosed
CN-116813647-A Nitrogen-containing condensed ring STING regulator compound, preparation method and application 上海凌达生物医药有限公司 2023-09-29 CN disclosed
CN-112778336-B Nitrogen-containing condensed ring STING regulator compound, preparation method and application 上海凌达生物医药有限公司 2023-05-05 CN disclosed
WO-2023064493-A1 COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES Clear Creek Bio, Inc. (US) 2023-04-20 WO disclosed
EP-4159725-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2023-04-05 EP disclosed
EP-4125914-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2023-02-08 EP disclosed
WO-2023009330-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC (US) 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236624-A1 Heterocyclic Compounds as RET Kinase Inhibitors RET, REL, BCR ALDH1A1 3019/4885HSD17B10 2544/4885ENPP2 1175/4885
US-20240018119-A1 CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS MAOA, DRD2, MAOB ALDH1A1 1214/4885HSD17B10 1454/4885ENPP2 1210/4885
US-20230339954-A1 Heterocyclic Compounds as RET Kinase Inhibitors RET, REL, BCR ALDH1A1 3019/4885HSD17B10 2544/4885ENPP2 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.